These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1500022)

  • 1. Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125.
    Högberg T; Kågedal B
    Gynecol Oncol; 1992 Aug; 46(2):191-8. PubMed ID: 1500022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer.
    Engblom PR; Grènman SE; Klemi PJ; Hirvonen TE; Rantanen VT; Salmi TA
    Acta Oncol; 1995; 34(6):783-5. PubMed ID: 7576746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas.
    Molina R; Ojeda B; Filella X; Borras G; Jo J; Mas E; Lopez JJ; Ballesta A
    Tumour Biol; 1992; 13(5-6):278-86. PubMed ID: 1290025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients.
    Hising C; Anjegård IM; Einhorn N
    Am J Clin Oncol; 1991 Apr; 14(2):111-4. PubMed ID: 2028919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
    Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
    Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G; Zippel HH; Würz H
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma.
    Zanaboni F; Vergadoro F; Presti M; Gallotti P; Lombardi F; Bolis G
    Gynecol Oncol; 1987 Sep; 28(1):61-7. PubMed ID: 2443433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
    Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
    Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
    Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
    Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
    Barillari P; Bolognese A; Chirletti P; Cardi M; Sammartino P; Stipa V
    Dis Colon Rectum; 1992 May; 35(5):471-6. PubMed ID: 1568399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
    Sevelda P; Wagner G
    Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
    Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
    Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of CA 125 as a marker of ovarian cancer.
    Markowska J; Manys G; Kubaszewska M
    Eur J Gynaecol Oncol; 1992; 13(4):360-5. PubMed ID: 1516589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.